Dr. Harrison on Choosing Frontline Treatment for RCC

Michael R. Harrison, MD, assistant professor of medicine, Duke Cancer Institute, discusses choosing frontline treatment for patients with renal cell carcinoma (RCC).

Considering the data with cabozantinib (Cabometyx) versus ipilimumab (Yervoy) and nivolumab (Opdivo), the field is changing so rapidly. There is going to be data of those combinations with checkpoint inhibitors and anti-VEGF agents, but the future lies in other combinations, explains Harrison.

According to Harrison, axitinib (Inlyta) would also be reasonable since it has a second-line approval and is being investigated in clinical trials.